Italia markets closed
FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.188,48 -670,80 (-1,12%)
Illumina, Inc. (0J8Z.L)
LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 07:01PM BST
| Chiusura precedente | 120,28 |
| Aperto | 121,25 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 118,93 - 123,53 |
| Intervallo di 52 settimane | 89,21 - 232,20 |
| Volume | |
| Media Volume | 8.482 |
| Capitalizzazione | 182,089M |
| Beta (5 anni mensile) | 1,19 |
| Rapporto PE (ttm) | 0,27 |
| EPS (ttm) | 4,55 |
| Prossima data utili | 02 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireMyriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera
© 2024 Yahoo. Tutti i diritti riservati.